Lampard Inquiry July 2026 hearings about vision based monitoring (Oxevision/LIO): a summary

 

Introduction 

The Lampard Inquiry is a statutory public inquiry investigating the deaths of patients under Essex mental health services between 2000 and 2023. The inquiry has come about following the tireless campaigning of bereaved families. Stop Oxevision have participated in the Inquiry since 2025 in our role as witnesses, represented by Bindmans LLP. In May and October 2025, we provided written and oral evidence to the inquiry regarding the use of Oxevision within Essex and more broadly. The Lampard Inquiry has also heard evidence from EPUT and Oxehealth/LIO as well as from bereaved families. We have also provided testimonies of patients subjected to the use of Oxevision – although these have not yet been disclosed (Stop Oxevision, witness statement one pg.4). 

The Lampard Inquiry has given thorough consideration to the use of Oxevision as part of its List of Issues, and has repeatedly indicated its intention to consider making interim national recommendations. Last year, in December 2025, Stop Oxevision’s barrister Brenda Campbell KC delivered a powerful speech on behalf of the core participants represented by the Bindmands Lampard Inquiry team. Brenda discussed submissions made on behalf of their clients to the Inquiry, calling on the Chair to make interim recommendations that EPUT:

 “take immediate steps to safely halt the use of Oxevision in inpatient bedrooms in all adult, older adult and children and young people wards within three months pending the final report and recommendation of this Inquiry”. 

The calls for theInquiry to issue interim recommendations calling EPUT to stop using Oxevision have been supported by the law firm HJA, who endorsed this on behalf of their clients, Bhatt Murphy for their bereaved/lived experience clients, and separately, Bhatt Murphy for INQUEST.

Three weeks of hearings in July 2026 considered – amongst other issues – the thematic issue of ‘The use of technology and observations’. Oral and written evidence regarding Oxevision was heard from EPUT staff members, bereaved families, and comparator Trusts regarding their use of Oxevision. The Inquiry also instructed expert witness reports and oral evidence from a consultant mental health nurse and two expert biostatisticians. Stop Oxevision attended these hearings and this article provides a summary of the content of the hearings, as related to Oxevision. 

We will not comment on the hearings beyond the topic of Oxevision, although we do not underestimate their importance. As always, we extend our love, rage and solidarity to all bereaved loved ones and patients courageously participating in the Inquiry in the long battle for justice and accountability. 

Throughout this report, we have linked to the associated hearing recordings, transcripts, reports and/or witness statements. Please note that all of these documents contain explicit discussion of self-harm and suicide, psychiatric abuse, sexual violence and other distressing content. We link to the original transcripts for reference purposes only. 

EPUT evidence

In March 2026, following a patient’s complaint escalated to the PHSO, EPUT were ordered to pay compensation to ‘Miss B’ in recognition of the failings in her treatment regarding the use of Oxevision. The PHSO also required that EPUT make changes to the latest iteration of its Oxevision policies. The Inquiry did not hear oral evidence from EPUT executive management during this set of hearings – indicating that this will instead be heard in October 2026 – however, documents disclosed by the Inquiry, and discussed during expert witness evidence, reveal that EPUT conducted a “rapid review” following the outcome of this complaint.  This identified two options “pausing the use of the system or continuing with immediate controls in place” (EPUT023601_KSZT01-177 pg.2). Subsequently, the Trust has changed its Oxevision policy to introduce an ‘opt in’ process whereby the system is turned off, and only activated if a patient provides ‘informed consent’ (EPUT023601_KSZT01-177 pg.5). They also commissioned a further “wider review of LIO assistive technology” (EPUT023601_KSZT01-177 pg.5). The Inquiry has also disclosed a 2025 assurance review regarding consent for Oxevision which offered “limited assurance” (EPUT020913_KSZT01-008 pg.2).

Last year, the Lampard Inquiry heard that while EPUT’s Oxevision policy stipulates that Oxevision must not be used in place of in-person observations, however this policy had not always been adhered to. In the July hearings, The Lampard Inquiry heard from several EPUT staff – primarily those working as ward and service managers. All current EPUT staff witnesses recognised that, contrary to this policy, Oxevision has been relied on in place of completing checks on patients in person (Chloe Cawston pg.244; Ian Arthur, pg.149; Brian O’Donnell, pg.47-48,63; Louise Borton, pg.97; Beverly Switzer, pg.209,215; Zoe Bunting, pg.22). On one ward, following the death of a patient who had not been observed in-person overnight (Bunting, pg.23), it was identified that the Oxevision monitors themselves had been installed in such a way for their functioning, that the patient beds were fixed out of the line of sight of the observation panel in the door. Importantly, the beds had not always been placed in this way (Bunting, pg.58; STAF024263 pg.1) further encouraging the use of Oxevision in place of going into the bedroom to observe a patient (Bunting, pg.58-59). 

Although Brian O’Donnell, former Clinical Lead for EPUT’s CAMHS wards, suggested that Oxevision may be beneficial for supporting nighttime observations, he also accepted that nighttime can be “riskiest time” for patients and that young people may appear to be asleep when they were actually awake (O’Donnell, pg.58-59) – meaning in-person checks and offering support are important. O’Donnell accepted that:

 “pressing a button and looking at somebody on a screen […] might give you a visual on them, but does [not] tell you about how they’re coping in that moment” (pg.46). 

He also recognised that this is not sufficient to consider whether their risk profile has increased (pg.47). O’Donnell provided a stark example of having viewed a patient through Oxevision who appeared to be walking around their bedroom but when visited in person had been at significant risk which wasn’t visible through the video (pg.47). He later agreed that “relying on the system or a system to observe patients can present a serious risk to patient safety” (pg.64). 

As has been raised in patient inquests and by bereaved core participants, the Inquiry heard that there was initially a total absence of staff training regarding the functions and intended use of Oxevision (Cawston pg.246; O’Donnell, pg.49). Staff had been permitted to work on the wards without having received formal training (Bunting, pg.11; 21, Dawn Low, pg.20,58; Switzer, pg.213-214). In one case, a former healthcare assistant – who worked as a bank HCA in 2022 as part of a Dispatches undercover documentary titled Hospital Undercover: Are Our Wards Safe? – had been entirely unaware of Oxevision and “didn’t even know it existed” until having worked a “few shifts” on the wards (Low, pg.58). One staff member described Oxvision inaccurately, suggesting ongoing misunderstandings about the technology and its limitations (Arthur, pg.155,168). Matron Louise Borton, said that she had:

 “concerns about the vision into the room and that people could be in a state of undress, that that could be opened up in the ward office. Potentially, if staff were that way inclined, they could take a photograph of that person in their room. And I had concerns about that.” (Borton, pg.86). 

Borton also acknowledged that she was not aware of any safeguards to prevent such misuse (pg.86). By contrast, Brian O’Donnell, former Clinical Lead on EPUT’s CAMHS wards, was asked: 

“going back to privacy concerns with children being recorded or observed continually in their bedrooms, was that a consideration at the time of the implementation of the pilot that you thought about, or that those around you were thinking about?” (O’Donnell, pg.51). 

O’Donnell responded:

 “Not really, no. No, looking back now, I don’t remember that being considered at all, to be honest” (pg.51). 

The Lampard Inquiry has repeatedly heard about “alert fatigue” associated with Oxevision. The EPUT staff witnesses described Oxevision alerts as going off “constantly”, as “oversensitive”, and as posing a distraction to staff – resulting in the alert being muted and the volume of monitors being turned down (Arthur, pg.132; O’Donnell, pg.60-61; Borton, pg.86). Dawn Low reported that  “if you were in that office, you could hear it [the Oxevision monitor] bleeping almost constantly” (Low, pg.59). Asked by Counsel to the Inquiry (CTI) what staff did in response to the alarms, Low replied “I think they were just carrying on and ignoring it” (pg.59). The Inquiry also heard that there is some duplication of technology, adding to the frequency of alerts (Arthur, pg.131-132).

The staff witnesses acknowledged that the presence of a video camera within patients’ bedrooms is an intrusion, and agreed that “patients have a right to know about Oxevision being used in their bedrooms, given the implications regarding their privacy” (Bunting, pg.31) and agreed that EPUT not seeking patient consent was an “oversight” (Arthur, pg.153). Staff also recognised that patients had not been appropriately informed that they were being recorded. Chloe Cawston said she could not “offer that assurance” that patients had always been “explicitly have been told that Oxevision cameras would be recording them 24/7” (Cawston, pg.247). Zoe Bunting recalled that posters had not initially been available (Bunting, pg.21), whilst Brian O’Donnell recalled having edited a template poster as he felt “this isn’t very clear” (O’Donnell, pg.53), and recalled “I don’t think that was enough information […] I don’t think it said that it’s recording 24/7” (pg.53). 

Staff recognised that Oxevision is intrusive; asked “to what extent is the use consistent with the principle of least restriction in mental health?”, Zoe Bunting responded that “I think it’s directly contrary to it. I think Oxevision is incredibly intrusive” (Bunting, pg.32). Healthcare assistant Beverly Switzer shared how “some patients did not like the idea that, of Oxevision being used and would cover up the camera with stickers or paper” (Switzer, pg.223); O’Donnell accepted that being watched through a video camera “would be really distressing” if someone had psychosis (O’Donnell pg.52); and Cawston agreed that issues around video recording patients, especially in the context of trauma and paranoia, would have been “foreseeable” (pg.249). 

Bunting also felt that Oxevision is “incredibly intrusive” (Bunting, pg.33), and that it does not have any “therapeutic benefit” (Bunting, pg.32), instead presenting a “barrier to engagement” (pg.12). Similarly, Louise Borton outlined in her witness statement that:

 “In my view, the use of this technology negatively impacted inpatient mental health care” and there is no “clinical justification for using it” (Borton, pg.84). 

When asked by CTI if she thought that there were any benefits to the use of Oxevision, Borton replied “Not personally, no” (pg.84). Whilst Cawston, Arthur and O’Donnell suggested that there were some benefits of the technology, when asked by CTI: “could those issues equally have been addressed by increasing staffing levels?”, O’Donnell agreed that “you can’t replace staffing and proper observation and engagement, yeah. I think that’s a valid point” (O’Donnell, pg.64).

 As CTI noted in their closing statement:

 “a recurring theme throughout the evidence was that technology cannot remedy deficiencies in staffing, supervision, training, or therapeutic engagement” (pg.135). 

Despite what had been reflected by EPUT staff in the hearings, a concerning independent assurance report in 2025 detailed that the consent policies in EPUT are still not being followed (EPUT020913_KSZT01-008). Furthermore, EPUT are conducting further reviews following the PHSO ruling in response to Miss B’s complaint (EPUT023601_KSZT01-177), Ian Arthur revealed that EPUT are still in the process of installing Oxevision within the final wards in the Trust (Arthur pg.168). 

On 13th July 2026, Victoria Sebastian, the mother of Elise Sebastian who died in 2021, gave powerful and devastating evidence, supporting calls for Oxevision to be banned. 

Comparator Trusts 

Whilst the Lampard Inquiry is focused on Essex, the Inquiry have always expressed their commitment to ensuring that their work holds national relevance, and taking a “careful evidence-led approach […] before reaching any conclusions or recommendations” (CTI closing statement pg.141-142). With this in mind, during 2026, the Inquiry sought further evidence from other NHS Trusts who use – or have used – Oxevision; as described by lead counsel to the Inquiry, Nick Griffin;

“this comparator evidence is intended to assist the Inquiry in assessing whether issues arising from the evidence concerning EPUT are Trust-specific or are reflected more widely in the implementation and use of Oxevision elsewhere” (hearing day 54, pg.8-9).

This was sought from from ELFT, NELFT, SLaM and Oxford Health as well as written and oral evidence from TEWV and Leicestershire Partnership.

In a paper read aloud during the hearings, CTI summarised that NELFT had conducted a review of Oxevision which:

 “concluded that there was insufficient evidence to suggest that Oxevision usage met its intended outcomes, that there was little evidence to suggest that consent obtained for the use of Oxevision was fully informed, voluntary, and free from coercion, that it risked subjecting vulnerable people to further restriction and potential harm, that there were legitimate concerns regarding the negative impact of Oxevision on therapeutic and personalised care and that there were significant safety concerns raised relating to its use” (hearing day 54, pg.152-153).

Quoting a report which we have previously discussed, the Inquiry said of Oxford Health that “at the end of the pilot, a lessons learned report was produced by Oxford Health to evaluate its deployment of Oxevision. The report noted that: “From the start of the project there has been a need for greater transparency and openness from the supplier”. And cited two instances where testing had to be suspended. On one such occasion, Oxevision use was suspended entirely pending the receipt of assurances from LIO, formerly Oxehealth, as to governance and security concerns” (hearing day 54, pg.163-164). The Inquiry also heard that SLaM used Oxevision for a short period of time until the settings were decommissioned and it was not rolled out further (pg.168). By contrast, ELFT continue to use Oxevision in 13 wards in the seclusion rooms, “consent to use Oxevision in patients’ rooms is not always sought. She explains that patients in seclusion areas are often acutely unwell, highly distressed and not in a position to engage meaningfully in a consent discussion” (pg.166). 

Tees Esk and Wear Valleys NHS Trust (TEWV)

With support of local and national groups, Stop Oxevision have recently written to TEWV to call on the Trust to suspend their use of Oxevision in all bedrooms, seclusion rooms and 136 suites. We continue to await a substantive response. 

Oral evidence was provided by Elspeth Devanney, Director of Nursing and Quality at TEWV alongside a witness statement provided by Beverly Murphy, Chief Nurse. During her evidence, Elspeth Devanney recognised the need for “an urgent review of current policy” (TEWV, pg.77-78). Indeed, TEWV are reportedly undertaking a review of Oxevision which may include  “our longer-term commitment to the system” (pg.49) and that “potentially…” “…whether it’s used at all, will be reconsidered” (pg.49). As summarized by Nick Griffin:

 “it’s all up for grabs, basically” (pg.49). 

The inquiry indicated that they will maintain contact with TEWV to “seek disclosure of the report and any further relevant documents” (pg.99). 

Despite this, Devanney confirmed that Oxevision was continuing to be installed on wards from 2026 and “And further wards to go live in the future” (pg.25). following a contract signed in 2021 (Beverly Murphy witness statement, pg.2). This means that “the majority” of TEWV wards have Oxevision installed (TEWV, pg.25) – over 50 wards (TEWV021331). According to our own research, TEWV are the most prolific users of Oxevision in the country, followed by CNTW then EPUT. However, Devanney admitted that some wards within TEWV, despite having Oxevision installed, were “hardly using the system at all” (TEWV, pg.85) with some areas, particularly secure wards, eating disorder wards and rehab units “where all patients have opted out” (pg.26,87,89). 

Whilst since 2024, TEWV now theoretically permit patients to opt out of the use of Oxevision, the inquiry heard that it may still be used without patient consent (pg.63-79). The TEWV policy is very similar to earlier versions of the EPUT policy (hearing day 55 pg.142), whereby Oxevision is turned on for all patients for the first 72 hours of admission (TEWV, pg.63) – “Even if a patient does not want the system activated it will be activated” (pg.65). CTI reflected that:

 “One of the things we don’t see here is patient choice?” and that “the patient’s objection is not viewed as the final word in terms of consent and the consent model used at TEWV?” (pg.69). 

Devanney agreed that this is “a significant omission” (pg.66) however, she reflected that the steering group felt the policy was compliant with the NHS England principles (pg.78).

The TEWV witness statement provided a lengthy list of the risks of Oxevision as follows (Beverly Murphy witness statement pg.9):

  1. “Relational unintended consequences of the system as patient behaviours change and use of the system to seek relational support; 
  2. An impact on privacy and dignity; 
  3. Patients report intrusive nature of critical alerts; 
  4. Staff report alert fatigue and prioritisation of the system alerts; 
  5. Technical reliability i.e. false alerts; 
  6. Alerts can interrupt therapeutic engagement; 
  7. Limited benefits in long stay environments; 
  8. latrogenic harm of use of the system i.e. increasing paranoia and perception of surveillance, impact on historical trauma; 
  9. Increased requests for CVD (clear video data); 
  10. Blanket approach within ward setting on alert configuration and unable to customise to individual patient; 
  11. Staff using the system as not initially intended and outside policy, i.e. using the system to conduct observations during the day or as a replacement of direct observations.”

TEWV’s witness statement “explains that at the time of the initial deployment there were no risks identified in the initial proposals” (Murphy witness statement pg.8, quoted in TEWV, pg.26). Elspeth Devanney agreed that it was “surprising” that risks weren’t identified (pg.27). However, as we highlighted in our letter to TEWV – which referenced the Trust’s own documentation obtained through FOIs conducted over the last 3 years – the Trust did anticipate a list of twenty ‘hazards’, all of the risks that came to later be realised, as Devanney agreed through a combination of “deaths or near misses, complaints, audits, patient feedback and the like” (TEWV, pg.80). 

The risks discussed in TEWV written and oral evidence included that Oxevision ‘alters patient’s behaviour’ in anticipation of alerts sounding (pg.81) whilst Devanney also acknowledged that:

 “Very often, when somebody is admitted to hospital, they’ve felt, whether they’re suffering from, you know, kind of an effective or a psychosis presentation, actually, their world doesn’t feel very safe and if somebody comes into an environment when then a camera is observing them, that can contribute to that feeling of not being safe” (pg.82). 

Devanney further shared that:

 “the amount of alerts that were happening across our inpatient areas was excessive and described as “unmanageable” by staff.” (pg.33) and that “alarm fatigue” is an issue (pg.34). 

In the context of this lengthy list of potential harms of Oxevision, the Inquiry queried how this expansion could be “reconciled” (pg.84). Given TEWV accepted the “quite a narrow context in which Oxevision can usefully be deployed” (pg.87) and recognise the material risks of the technology (Murphy witness statement pg.9) we keenly await the outcome of the TEWV Oxevision review and reiterate our calls for the technology to be removed in full. 

Leicestershire Partnership NHS Trust (LPT)

In the afternoon of the 21st July, the Inquiry heard from Andres Freire-Patino, head of business and Transformation for the Directorate of Mental Health at LPT. The story was covered by BBC East Midlands, including an interview with Stop Oxevision. 

Freire-Patino confirmed that LPT originally intended to install Oxevision on seven wards (LPT, pg.110), following a business case which Oxehealth “assisted” in drafting (pg.122). However, Oxevision was only ever used on two wards (pg.111), with an initial pilot between “December ’22 and February 2023” (pg.108). However this was followed by a “pause of about 20 months and […] the pilot [was] relaunched as a second pilot from 14 November 2024 to 10 January 2025” (pg.108). Despite this, LPT were charged for the full 3 year/seven ward contract by Oxehealth (LPT022555_NP08-LPT, pg.2) in addition to paying a £60,000 ‘end of contract’ fee. This followed LPT being unaware of a 6 months’ notice ahead of the contract end date to cancel the contract and Oxehealth offering ‘counter options’ involving installing Oxevision on more wards but LPT ultimately decided to terminate the use of the technology (LPT022555_NP08-LPT, pg.6).

In 2023, LPT paused the initial Oxevision pilot following concerns regarding high staff turnover, staff training, issues with wifi connectivity, duplication of technology. Furthermore:

 “of particular significance, feedback received from staff gave rise to concerns that the technology could be susceptible to misuse. Specifically, it was identified that a member of staff could, in principle, use Oxevision to monitor a patient within their bedroom without any corresponding alert being generated or any notification being escalated to other members of staff on duty at the time” (LPT pg.117-118; witness statement of Andres Freire-Patino, pg.2).

Following a long period of re-evaluation, a second eight-week pilot followed a new approach whereby one ward would “only use Oxevision for completing observations from 11 pm until 7.30 in the morning” (pg.126). The second pilot focused on using Oxevision for the purposes of reducing nighttime disturbance, on the basis that, “Oxevision gives us the opportunity to not have to enter the patient’s room therefore not causing as much disturbance” (pg.128) both for patients on level 1 and 2 (i.e. checks between 10 minutes to one hour) (pg.129). As was heard by EPUT staff witnesses and the Inquiry’s mental health nurse expert witness, there are substantial concerns regarding the safety and acceptability of replacing in-person observations with viewing a video of patients remotely. Nevertheless, LPT reported that due to the limitations in the system’s ability to provide vital signs, patients continued to be disturbed during the night (witness statement of Andres Freire-Patino, pg.13; LPT022552_NP09, pg.4,9,13).

During the pilot it was reported that “less than half” of patients consented to the use of Oxevision, with a point at which only one patient on the 14 bed ward had agreed to its use (LPT, pg.147; LPT022555_NP08, pg.5). There were also patients who withdrew their ‘consent’ “when they understood that there were cameras” (LPT022555_NP08, pg.5) illustrating that such ‘consent’ was not informed. One patient slept in an interview room and had to be moved to a different ward due to refusing to enter her room even when the camera was turned off (LPT022552_NP09-LPT, pg.12). The low number of patients consenting was reported as an important factor in the decision to not continue with the use of the technology (LPT, pg.150). A document read aloud to the inquiry states: “Oxevision is a high-cost system and although there have been some benefits to patient sleep, due to the period of time of the pilot, there is insufficient evidence to demonstrate any impact on patient outcomes” (LPT, pg.155). 

Expert witness – mental health nurse 

The inquiry instructed a consultant mental health nurse, Jill Archibald, who works at Cumbria, Northumberland, Tyne and Wear NHS Trust (CNTW) as an expert witness. Her 104-page report covered the topic of observations and technology. The first section of her report and evidence detailed the need for observations to be about meaningful engagement with the patient and offering support. As summarised by CTI in their closing statement, “Ms Archibald’s view was that:

“Ultimately, observations are most effective when they remain human, relational, and patient-centred, rather than becoming purely procedural or surveillance based” CTI closing statement pg.143. 

Archibald was clear and unequivocal that it is not safe or permissible to use vision-based monitoring technologies, such as Oxevision, to replace in-person observations. Her report highlighted “Remote viewing or reliance on Oxevision is insufficient to determine whether a patient is physically well, emotionally distressed, deteriorating, or in need of urgent observation” (Jill Archibald hearing transcript pg.139). She also stated that Oxevision should not be used for the purpose of providing a ‘less intrusive’ observation of someone who should otherwise be on 1:1 (pg.184). Archibald was clear that she doesn’t “think it’s an essential piece of equipment to keep somebody safe” (pg.113), with her evidence instead recognising the “the risk of relying on a technology instead of human observation” (pg.139). 

Archibald recognised that Oxevision is inherently intrusive. She states in her report that:

 “In my view, the ability to obtain a clear view, use pixelated images and retain clear view data for up to 24 hours creates a significant intrusion into a private space” (Jill Archibald hearing transcript pg.125). 

She also reflected concerns that “the device itself doesn’t obviously look like a camera, it’s a device that I’ve never seen anything that looks like it before” (pg.121) which may contribute to patients not being appropriately aware that they are being recorded. Asked about the fact that Oxevision records 24-hours a day, Archibald shared “I struggle to understand why it needs to be on. And I do – it is concerning, and also it’s not made explicit to patients that that is the case” (pg.124). She continued, “I think it goes beyond being absolutely necessary […] I don’t think 24-hour filming of them in their private space is absolutely necessary or justified” (pg.125).

Oxehealth/LIO marketing materials have long suggested that Oxevision, and its continuous video recording, is actually less intrusive than patients being observed by staff in person and describe blurred video as “anonymous”. However, Archibald’s evidence firmly contested this position. Asked whether pixilation “actually reduces privacy and dignity concerns” (Archibald, pg.117) Archibald responded:

 “When you’re looking at the pixelated image you don’t know what you’re about to see, so you don’t know if a patient is engaging in private time or getting changed. And even though you might not be able to solely identify the patient from the image, you still get an insight into what they’re doing in their private space” (pg.117). 

She continued, “if you knock on a bedroom door, the patient might say, “Can you give me a minute?” So you’re given a warning but with a pixelated image there is no warning of the image” (pg.118). Archibald later reflected on the fact that:

 “I would see it more distressing to be observed remotely because you’re not aware of when and how frequent it’s happening, where in the room you’re aware.” […] “And you can raise — and it empowers the patient to raise an objection” (pg.181). 

Moreover, Archibald recognised the profound impact this has on  patients, sharing that:

 “some of our patients already have — are paranoid and struggle to trust professionals, and struggle to trust anybody, so that can reinforce that we’re not to be trusted and equally increase their paranoia. I’ve witnessed some patients scream at the device thinking … and it’s — yeah, it can be confusing for some” (pg.121-122). 

She continued:

“I have had patients that have brought the — smashed the device or covered it up. And sleep on the sofas in the main areas, because they feel uncomfortable with the device in the room” (pg.122). 

She also discussed how Oxevision may replicate trauma:

 “most people have not been filmed in their private area in any aspects of their life but for patients who have suffered significant trauma, that might have been the case. So it can be very traumatic. It’s very intrusive” (pg.126). 

However, Archibald further agreed with a follow up question from CTI to recognise that “the point here is actually, patients who haven’t, for example, a patient who is not paranoid or doesn’t have a specific trauma, do you agree that that feeling of loss of privacy can be equally keenly felt by them?” (pg.126). 

This has been long documented by Stop Oxevision for years. Whilst we have always been aware of patients who have previous trauma around surveillance being affected particularly acutely, we have also heard from countless patients who have experienced trauma as a result of being surveilled through Oxevision during an admission. 

In terms of the capabilities of the system, Archibald recognised the limited functions of Oxevision, and the risk that these are misunderstood, with the system offering reassurance beyond its capabilities. In terms of vital signs readings, Archibald recognised that “although it offers a 15-minute window it would not be used to replace NEWS or inform clinical assessment” (pg.127) and that “The risk of that is the professional or the person using it might interpret it as a full set of observations when in fact it’s not” (pg.127-128). 

Her evidence also discussed the use of Oxevision to reduce the disturbance of patients at night. Archibald reflected that nighttime observations are important as “nighttimes can be incredibly difficult for a lot of patients, for lots of various reasons. There’s a lot of quiet time, a lot of time for reflection. People tend to miss their families more. And equally, it can be a trauma response. So nighttimes tend to be quite risky” (pg.140). She later agreed that:

 “withdrawing regular nighttime physical checks that provide a level of in-person reassurance and replacing them with remote observation or surveillance, far from being clinically justified to promote sleep, might in fact be clinically detrimental for some patients” (pg.178-179). 

She also reflected that there are “lots of things in the environment that we can do rather than solely relying on technology” in order to reduce disturbance at night (pg.139-140).

Archibald was asked about the EPUT and TEWV policies where Oxevision is turned on for all patients unless they specifically object to its use (pg.142), reflecting that “I struggle to grasp that it still falls down to the MDT to make a decision when the patient either has capacity and refuses, or lacks capacity but still doesn’t wish to use it” (pg.146). Archibald’s report stated that:

 “this [‘consent’ model] is difficult to reconcile with a genuine consent-based patient-centred and rights-based approach, particularly where the patient was informal or where the legal basis for continued monitoring was not clearly identified” (pg.146-147). 

She reflected concerns that this “risked placing organisational approval above the patient’s expressed refusal” (pg.146) and may risk informal patients discharging themself (pg.147). However, it should be noted that, whilst Archibald was preparing her report, and until just two days before her oral evidence, CNTW was operating a materially identical ‘opt-out policy’ whereby Oxevision was activated for all patients on admission (private correspondence from CNTW; CNTW Oxevision policy). 

By way of summary, Archibald reflected that:

 “in my experience, it’s [Oxevision has] not saved time. It’s added an extra layer of work on, but what it has done is give us an insight into what is going on inside patients’ bedrooms when we’re not there. That is what it has given, but you’ve got to balance of is that absolutely necessary?” (Archibald, pg.161). 

Whilst Archibald was at pains to emphasise that she “welcome[s] assistive technology” (pg.160) and is still “on the fence” (pg.162) about Oxevision, a section of her report was read aloud which stated that:

“I remain concerned that the introduction of such technology into inpatient mental health settings carries significant clinical, ethical and human rights implications. A camera sensor or alert cannot understand distress, hopelessness, shame, agitation, elation, paranoia, trauma, responses or the meaning of the patient’s behaviour. It cannot determine whether a patient is becoming more withdrawn, more frightened, more suicidal, more suspicious, or more in need of a human connection” (pg.161).

 A particularly striking moment in her evidence was that Archibald reflected “if I was a patient or a family member, it’s not something that I would be comfortable having. And I think, before you do anything or suggest anything to your patients you need to ask: is it good enough for me and is it good enough for my family?” (pg.125-126). 

While Archibald’s evidence covered a great deal, the main elements were clear – as patients, bereaved families and Stop Oxevision have argued for years, Oxevision has significant, detrimental implications for the privacy and safety of patients.

Expert statisticians  

The Inquiry instructed two expert health statisticians, Professor Christl Donnelly and Dr Maria Christodoulou, from the University of Oxford. They prepared a 47-page report summarising the published academic literature regarding Oxevision and provided oral evidence. Their report concluded that:

 “the current evidence provides only limited and cautious support for the use of Oxevision and related [vision-based patient monitoring systems] in mental health inpatient settings. It suggests that the technology is technically feasible and may have potential operational applications, but it does not provide strong, independent evidence of clinical effectiveness, improved patient safety, acceptability or cost-effectiveness in mental health inpatient settings” (report, pg.5). 

Prof Donnelly and Dr Christodoulou further agreed that “there was no evidence that could be given even moderate weight in support of the […] clinical effectiveness of Oxevision in the inpatient mental health context” (Donnelly and Christodoulou, pg.117). 

Prof Donnelly and Dr Christodoulou provided assistance to the inquiry regarding a number of statistical concepts such as hypothesis testing, statistical significance and study design. They discussed the limitations of the studies concluding that these can only be given low evidential weight, echoing the findings of 2024 NIHR systematic review.

Their evidence acknowledged that there had been a recent retraction of an article, made between the period in which they prepared their report and gave oral evidence. They acknowledged that it is “possible, notwithstanding that peer review process, for papers to be published which contain important methodological limitations or even errors and that they would still be published” (pg.14) and that “the goal is to weed out any issues, identify them in the process of peer review, but you only have a number of peer reviewers and they may not have expertise or the full knowledge of everything that might be there” (pg.14-15). However,  Dr Christodoulou reflected that retractions are “not overall a common occurrence” (pg.16). 

Their report stated that the predominance of studies being authored by those with conflicts of interest reflected that whilst not uncommon in research:

 “independence is one thing that you would aim for in the strongest (unclear) evidence, because you would like people not to have that sort of skin in the game. So you would like the scientists who are undertaking the study not to benefit if a particular outcome happens...” (pg.31) 

and that:

 …“it’s important for people to realise whether or not there was any potential motivation to present things in a slightly better light.” (pg.37)

By contrast, when discussing the two systematic reviews, Professor Donnelly and Dr Christodoulou noted the comparative strength of these, outlining how the study conducted by Griffiths et al in 2024 concluded that “there was insufficient evidence, as they say themselves, to suggest that surveillance technology in inpatient mental health settings are achieving their intended outcomes such as including safety and reducing costs.” (pg.61). This was echoed in a second review commissioned by CQC. Agreeing with the findings of these earlier reviews, they recognised the limited lived experience involvement in the studies as a “common feature” of the research (pg.62-63) and that  “there is little focus on” patient acceptability in the studies they reviewed (pg.119)

They expressed particular caution regarding the economic analyses. This included the paper which was subsequently retracted (pg.82) but in summary the articles “provide suggestions that there could be cost savings in the wards in which they had looked at them, but I would say it’s not convincing evidence.” (pg.89). However, they agreed that “In terms of the way these figures are framed by the authors […] in a way that these are substantial savings to be made” (pg.122). They recognised that it was “possible” that this would risk mental health trusts thinking Oxevision “produces a cash saving when in fact it might not” (pg.123-124). 

The expert statisticians’ evidence corroborates the arguments Stop Oxevision have been making for years – including within our written and oral evidence provided to the Lampard Inquiry – that the evidence underpinning the use of this technology is extremely thin and risks misrepresentation. You can read more of our published work on this particular issue here and here. 

Next steps 

In the closing statement from counsel to the Inquiry, Nick Griffin KC offered important reflections on the evidence heard regarding Oxevision. He provided a summary that:

 “Taken together, the expert evidence has provided the Inquiry with something of a wider national importance. Rather than asking simply whether technology can be deployed, the evidence has consistently returned to a more fundamental question: what genuinely improves patient safety, therapeutic care, and patient experience within mental health inpatient services? And that broader question lies at the heart of this Inquiry” (pg.145). 

The Inquiry indicated that it will further consider evidence regarding Oxevision during “the reframed Interim Recommendations Hearing in October” (pg.146). The Chair has also indicated that she “would be assisted at least by hearing further evidence from EPUT around their use of technology in this way and from LIO, formerly Oxehealth” (pg.146). As outlined previously, in 2025, Bindmans LLP, on behalf of bereaved core participants and Stop Oxevision, shared submissions to the inquiry calling on them to implement interim recommendations for EPUT to stop using Oxevision. Stop Oxevision will continue to support the Inquiry in our capacity as witnesses to support the Inquiry in its vital work to lead vital improvements in mental healthcare provision within Essex and nationally. 

The Lampard Inquiry public hearings resume between 5th October to 22nd October 2026, held publicly at Chelmsford Civic Centre (pg.146). 

3 responses to “Lampard Inquiry July 2026 hearings about vision based monitoring (Oxevision/LIO): a summary”

  1. […] first called for in December 2025, Following the Lampard Inquiry July and October 2026 hearings, lawyers for Stop Oxevision, bereaved families and the charity INQUEST […]

  2. […] Lampard Inquiry July 2026 hearings about vision based monitoring (Oxevision/LIO): a summaryArticle by and via Stop Oxevision. […]

  3. […] in England. We have previously provided updates following hearings held in May/October 2025 and July 2026. This update covers a summary of the evidence provided by NHS England in October 2026, we will […]

Leave a Reply